Gilead Sciences Inc

GILD:NASDAQ
RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/15/21 EST
63.30quote price arrow down-0.03 (-0.05%)
Volume
383,006
Close
63.33quote price arrow up+0.93 (+1.49%)
Volume
8,938,458
52 week range
56.56 - 85.97

...

Loading . . .

KEY STATS

  • Open62.30
  • Day High63.60
  • Day Low62.13
  • Prev Close62.40
  • 52 Week High85.97
  • 52 Week High Date03/19/20
  • 52 Week Low56.56
  • 52 Week Low Date12/31/20
  • Market Cap79,386.06M
  • Shares Out1,253.53M
  • 10 Day Average Volume10.68M
  • Dividend2.72
  • Dividend Yield4.29%
  • Beta0.45
  • 1 Year % Change0.21

RATIOS/PROFITABILITY

  • EPS (TTM)0.96
  • P/E (TTM)65.80
  • Fwd P/E (NTM)8.91
  • EBITDA (MRQ)3,917.00M
  • ROE (MRQ)6.67%
  • Revenue (MRQ)23,147.00M
  • Gross Margin (MRQ)79.02%
  • Net Margin (MRQ)5.33%
  • Debt To Equity (MRQ)167.90%

EVENTS

  • Earnings Date02/02/2021
  • Ex Div Date12/14/2020
  • Div Amount0.68
  • Split Date-
  • Split Factor-

Latest GILD News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Related Video

VIDEO2:5002:50
Gilead Sciences CEO on raising full-year guidance due to remdesivir sales

Profile

MORE
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy...
Daniel O'Day
Chairman
Andrew Dickinson
Chief Financial Officer
Jyoti Mehra
Executive Vice President
Brett Pletcher
Executive Vice President
Address
333 LAKESIDE DR
Foster City, CA
94404
United States